{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-157030","form_type":"8-K","ticker":"MCHX","cik":"0001224133","company_name":"MARCHEX INC","filed_at":"2026-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.051944+00:00","generated_at":"2026-05-15T06:01:29.513351+00:00","sec_items":["1.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Marchex settles civil lawsuit for $2M, payments spread over 13 months","bullets":["Settlement agreement signed April 14, 2026 resolves all claims in Barnard and McEvenue v. Marchex.","Total payment: $1M by May 14, 2026 ($750k cash + $250k escrow release).","Additional $500k due Nov 16, 2026 and $500k due May 17, 2027.","Company had previously recorded expense accrual in 2025 financials for this settlement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-157030","json":"https://secwatch.observer/filing/0001193125-26-157030.json","markdown":"https://secwatch.observer/filing/0001193125-26-157030.md","text":"https://secwatch.observer/filing/0001193125-26-157030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/mchx-20260414.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:01:29.513351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b672021160e91d179ed162efe45aa2bf558bd0b0","claim":"MARCHEX INC entered into Settlement Agreement valued at $750,000 (and agree to the release of $250,000 held in escrow by U.S. Bank) (effective 2026-04-14).","evidence_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001437749-26-015945","ticker":"ICCC","company_name":"IMMUCELL CORP /DE/","filed_at":"2026-05-08T23:59:59+00:00","headline":"ImmuCell settles Norbrook dispute, to receive $2M payment","event_type":"litigation","sec_items":["1.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-015945","json":"https://secwatch.observer/filing/0001437749-26-015945.json","markdown":"https://secwatch.observer/filing/0001437749-26-015945.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/iccc20260508_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","comparable_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm"}},{"accession":"0001437749-26-014906","ticker":"SGRP","company_name":"SPAR Group, Inc.","filed_at":"2026-05-05T23:59:59+00:00","headline":"SPAR Group settles arbitration with founder Robert Brown; extends CIC agreement to 2028","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-014906","json":"https://secwatch.observer/filing/0001437749-26-014906.json","markdown":"https://secwatch.observer/filing/0001437749-26-014906.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/0001437749-26-014906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/sgrp20260505_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","comparable_excerpt":"On May 1, 2026, the Company entered into a Settlement Agreement and Release with Robert G. Brown and SPAR Business Services, Inc. allowing for a dismissal of the Arbitration action between the Company and Robert G. Brown.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/0001437749-26-014906-index.htm"}},{"accession":"0001805651-26-000038","ticker":"MKTW","company_name":"MARKETWISE, INC.","filed_at":"2026-04-24T23:59:59+00:00","headline":"MarketWise settles arbitration with former CEO for $12.16M cash, redeems 520,867 units, terminates TRA rights","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001805651-26-000038","json":"https://secwatch.observer/filing/0001805651-26-000038.json","markdown":"https://secwatch.observer/filing/0001805651-26-000038.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/0001805651-26-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/mktw-20260421.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","comparable_excerpt":"On April 21, 2026, Marketwise, Inc. (the “Company”) and its subsidiary, MarketWise, LLC (together with the Company, “MarketWise”), entered into a Settlement Agreement and Release (the “Settlement Agreement”) with Mark P. Arnold, the Company’s former Chief Executive Officer, and JAMA 2021, LLC (together with Mr. Arnold, the “Arnold Parties”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/0001805651-26-000038-index.htm"}},{"accession":"0001628280-26-024527","ticker":"CPT","company_name":"CAMDEN PROPERTY TRUST","filed_at":"2026-04-09T23:59:59+00:00","headline":"Camden Property Trust settles RealPage antitrust class action for $53M","event_type":"litigation","sec_items":["1.01","7.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-024527","json":"https://secwatch.observer/filing/0001628280-26-024527.json","markdown":"https://secwatch.observer/filing/0001628280-26-024527.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/906345/000162828026024527/0001628280-26-024527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906345/000162828026024527/cpt-20260407.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","comparable_excerpt":"On April 7, 2026, Camden Property Trust, on behalf of itself and related entities (collectively, the “Company”) entered into a binding term sheet for a settlement with the named plaintiffs in the Class Action Litigation, individually and on behalf of the class members (together, the “Plaintiffs”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/906345/000162828026024527/0001628280-26-024527-index.htm"}},{"accession":"0001829126-26-003120","ticker":"SLND","company_name":"Southland Holdings, Inc.","filed_at":"2026-04-02T23:59:59+00:00","headline":"Southland subsidiary settles WA convention center lawsuit; sureties to pay additional $26.5M","event_type":"litigation","sec_items":["1.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-003120","json":"https://secwatch.observer/filing/0001829126-26-003120.json","markdown":"https://secwatch.observer/filing/0001829126-26-003120.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1883814/000182912626003120/0001829126-26-003120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1883814/000182912626003120/southland_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","comparable_excerpt":"On March 27, 2026, American Bridge Company (“American Bridge”), a wholly owned subsidiary of Southland Holdings, Inc. (the “Company”), entered into a Settlement Agreement and Release of Claims (the “Settlement Agreement”) with Clark/Lewis, a Joint Venture (“Clark/Lewis”), certain sureties of American Bridge (the “Sureties”), the Washington State Convention Center (“WSCC”), and American Bridge’s litigation counsel.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1883814/000182912626003120/0001829126-26-003120-index.htm"}},{"accession":"0001140361-26-010656","ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2026-03-23T23:59:59+00:00","headline":"Roivant subsidiary Genevant settles LNP patent litigation with Moderna; includes license and payments","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-010656","json":"https://secwatch.observer/filing/0001140361-26-010656.json","markdown":"https://secwatch.observer/filing/0001140361-26-010656.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/ef20068452_8ka.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","comparable_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm"}},{"accession":"0001193125-26-117652","ticker":"OESX","company_name":"ORION ENERGY SYSTEMS, INC.","filed_at":"2026-03-20T23:59:59+00:00","headline":"Orion settles Voltrek earnout dispute for $3M cash; solar PPA exit adds $1.3M offset","event_type":"litigation","sec_items":["1.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-117652","json":"https://secwatch.observer/filing/0001193125-26-117652.json","markdown":"https://secwatch.observer/filing/0001193125-26-117652.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1409375/000119312526117652/0001193125-26-117652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1409375/000119312526117652/oesx-20260317.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","comparable_excerpt":"On March 17, 2026, Orion Energy Systems, Inc. and its subsidiaries (collectively, the “ Company ”) entered into a settlement agreement (the “ Settlement Agreement ”) with Final Frontier, LLC (“ Final Frontier ”) and Kathleen M. Connors (“ Ms. Connors ”), personally and as Trustee of the Kathleen M. Connors 2019 Revocable Trust","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1409375/000119312526117652/0001193125-26-117652-index.htm"}},{"accession":"0001193125-26-117913","ticker":"RGNX","company_name":"REGENXBIO Inc.","filed_at":"2026-03-20T23:59:59+00:00","headline":"REGENXBIO settles GSK sublicense fee dispute for $10M","event_type":"litigation","sec_items":["1.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-117913","json":"https://secwatch.observer/filing/0001193125-26-117913.json","markdown":"https://secwatch.observer/filing/0001193125-26-117913.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/rgnx-20260318.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","comparable_excerpt":"On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}